Passive-active immunisation against hepatitis B: immunogenicity studies in adult Americans (Q42241107)

19 October 2017

Passive-active immunisation against hepatitis B: immunogenicity studies in adult Americans (English)

1 reference

19 October 2017

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6110818

7 August 2023

author name string

W. Szmuness

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6110818

7 August 2023

C. E. Stevens

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6110818

7 August 2023

W. R. Oleszko

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6110818

7 August 2023

A. Goodman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6110818

7 August 2023

language of work or name

English

0 references

publication date

1 March 1981

1 reference

19 October 2017

14 March 1981

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6110818

full work available at URL

7 August 2023

https://api.elsevier.com/content/article/PII:S0140673681920304?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(81)92030-4

https://api.elsevier.com/content/article/PII:S0140673681920304?httpAccept=text/plain

7 August 2023

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(81)92030-4

7 August 2023

1 reference

19 October 2017

1

1 reference

19 October 2017

8220 Pt 1

1 reference

19 October 2017

575-577

1 reference

Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States

19 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Hepatitis B vaccine: immune responses in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Hepatitis B Immune Globulin for Accidental Exposures among Medical Personnel: Final Report of a Multicenter Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Hepatitis B Immune Globulin: Final Report of a Controlled, Multicenter Trial of Efficacy in Prevention of Dialysis-Associated Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Large-scale efficacy trials of hepatitis B vaccines in the USA: Baseline data and protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Infectious hepatitis; length of protection by immune serum globulin (gamma globulin) during epidemics.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Infectious hepatitis. Studies on the effect of gamma globulin and on the incidence of inapparent infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Antibody against serum-hepatitis antigen. Prevalence and potential use as immune serum globulin in prevention of serum-hepatitis infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Hemagglutination Assay for Antigen and Antibody Associated with Viral Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Hepatitis B immune serum globulin in prevention of nonparenterally transmitted hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Passive-active immunity from hepatitis B immune globulin. Reanalysis of a Veterans Administration cooperative study of needle-stick hepatitis. The Veterans Administration Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2881%2992030-4

7 January 2021

Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association

16

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(81)92030-4

7 August 2023

Identifiers

1 reference

19 October 2017

1 reference